TNF and inflammatory bowel disease: Anti-tumor necrosis factor (anti-TNF) therapies remain an important part of the therapeutic armamentarium in the treatment of moderate to severe IBD.2,3 Newer biologic agents approved for CD and UC include Ustekinumab (IL12/23, Stelera) and Vedolizumab (α4β7, Entyvio), which specifically target alternate pathways of inflammation.